Clinical Trials · NCT01205685
Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Enrollment
- 11
- Start date
- May 2010
- Locations
- 3 sites, United States
- Primary endpoint
- Anti-tumor Activity of OSI-906